By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Merck sees over $5 billion opportunity in Cidara's experimental flu drug - 2‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- 3Trump administration plan to reduce access to some student loans angers nurses, health care groups
- 4Becoming the best at Discussion: Individual Procedures
- 5Chevron Says Damage at Wheatstone LNG Will Hamper Restart
- Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- Top notch DSLR Cameras for Photography Devotees
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- The Best 15 Applications for Efficiency and Association
- Surveys of Thrillers That Re-imagined the Class
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- I read 115 books this year. 'Wuthering Heights,' 'Heart the Lover' and 'The House of My Mother' were among my 10 favorites.
